The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
Paolo Ghia, MD, PhD from the San Raffaele Hospital, Milan, Italy, gives us an insight into the possible association of chronic lymphocytic leukemia (CLL) patients who have mutated immunoglobulin receptors and their good response to chemoimmunotherapy (i.e. longer progression-free and overall survival), compared to those without mutations. He mentions a study that is currently being conducted to investigate this phenomenon. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
